Literature DB >> 22287205

Targeting the enhancer of zeste homologue 2 in medulloblastoma.

Irina Alimova1, Sujatha Venkataraman, Peter Harris, Victor E Marquez, Paul A Northcott, Adrian Dubuc, Michael D Taylor, Nicholas K Foreman, Rajeev Vibhakar.   

Abstract

Enhancer of zeste homologue 2 (EZH2) is the catalytic subunit of Polycomb repressive complex 2 that catalyzes the trimethylation of histone H3 on Lys 27, and represses gene transcription. EZH2 enhances cancer-cell proliferation and regulates stem cell maintenance and differentiation. Here, we demonstrate that EZH2 is highly expressed in medulloblastoma, a highly malignant brain tumor of childhood, and this altered expression is correlated with genomic gain of chromosome 7 in a subset of medulloblastoma. Inhibition of EZH2 by RNAi suppresses medulloblastoma tumor cell growth. We show that 3-deazaneplanocin A, a chemical inhibitor of EZH2, can suppress medulloblastoma cell growth partially by inducing apoptosis. Suppression of EZH2 expression diminishes the ability of tumor cells to form spheres in culture and strongly represses the ability of known oncogenes to transform neural stem cells. These findings establish a role of EZH2 in medulloblastoma and identify EZH2 as a potential therapeutic target especially in high-risk tumors.
Copyright © 2012 UICC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22287205      PMCID: PMC3375399          DOI: 10.1002/ijc.27455

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  32 in total

1.  Role of histone H3 lysine 27 methylation in Polycomb-group silencing.

Authors:  Ru Cao; Liangjun Wang; Hengbin Wang; Li Xia; Hediye Erdjument-Bromage; Paul Tempst; Richard S Jones; Yi Zhang
Journal:  Science       Date:  2002-09-26       Impact factor: 47.728

2.  Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma.

Authors:  Raymond K Mulhern; Shawna L Palmer; Thomas E Merchant; Dana Wallace; Mehmet Kocak; Pim Brouwers; Kevin Krull; Murali Chintagumpala; Robyn Stargatt; David M Ashley; Vida L Tyc; Larry Kun; James Boyett; Amar Gajjar
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

3.  Expression profile of an operationally-defined neural stem cell clone.

Authors:  Mark A Parker; Julia K Anderson; Deborah A Corliss; Victoria E Abraria; Richard L Sidman; Kook In Park; Yang D Teng; Douglas A Cotanche; Evan Y Snyder
Journal:  Exp Neurol       Date:  2005-08       Impact factor: 5.330

4.  EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.

Authors:  Ingeborg M Bachmann; Ole J Halvorsen; Karin Collett; Ingunn M Stefansson; Oddbjørn Straume; Svein A Haukaas; Helga B Salvesen; Arie P Otte; Lars A Akslen
Journal:  J Clin Oncol       Date:  2005-12-05       Impact factor: 44.544

5.  c-myc overexpression causes anaplasia in medulloblastoma.

Authors:  Duncan Stearns; Aneeka Chaudhry; Ty W Abel; Peter C Burger; Chi V Dang; Charles G Eberhart
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

6.  Dickkopf-1 is an epigenetically silenced candidate tumor suppressor gene in medulloblastoma.

Authors:  Rajeev Vibhakar; Greg Foltz; Jae-Geun Yoon; Lorie Field; Hwahyung Lee; Gi-Yung Ryu; Jessica Pierson; Beverly Davidson; Anup Madan
Journal:  Neuro Oncol       Date:  2007-02-28       Impact factor: 12.300

7.  Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.

Authors:  Phillip H Abbosh; John S Montgomery; Jason A Starkey; Milos Novotny; Eleanor G Zuhowski; Merrill J Egorin; Annie P Moseman; Adam Golas; Kate M Brannon; Curtis Balch; Tim H M Huang; Kenneth P Nephew
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

8.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells.

Authors:  Celina G Kleer; Qi Cao; Sooryanarayana Varambally; Ronglai Shen; Ichiro Ota; Scott A Tomlins; Debashis Ghosh; Richard G A B Sewalt; Arie P Otte; Daniel F Hayes; Michael S Sabel; Donna Livant; Stephen J Weiss; Mark A Rubin; Arul M Chinnaiyan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-19       Impact factor: 11.205

Review 9.  Epigenetics and cancer.

Authors:  Anders H Lund; Maarten van Lohuizen
Journal:  Genes Dev       Date:  2004-10-01       Impact factor: 11.361

10.  Abnormal expression of REST/NRSF and Myc in neural stem/progenitor cells causes cerebellar tumors by blocking neuronal differentiation.

Authors:  Xiaohua Su; Vidya Gopalakrishnan; Duncan Stearns; Kenneth Aldape; Fredrick F Lang; Gregory Fuller; Evan Snyder; Charles G Eberhart; Sadhan Majumder
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

View more
  35 in total

1.  EZH2 orchestrates apicobasal polarity and neuroepithelial cell renewal.

Authors:  Naiara Akizu; Marian A Martínez-Balbás
Journal:  Neurogenesis (Austin)       Date:  2016-11-17

2.  Laminin-adherent versus suspension-non-adherent cell culture conditions for the isolation of cancer stem cells in the DAOY medulloblastoma cell line.

Authors:  Javier de la Rosa; Ander Sáenz Antoñanzas; Mehdi H Shahi; Bárbara Meléndez; Juan A Rey; Javier S Castresana
Journal:  Tumour Biol       Date:  2016-06-15

3.  Epigenetic states of cells of origin and tumor evolution drive tumor-initiating cell phenotype and tumor heterogeneity.

Authors:  Kin-Hoe Chow; Dong-Mi Shin; Molly H Jenkins; Emily E Miller; David J Shih; Seungbum Choi; Benjamin E Low; Vivek Philip; Brad Rybinski; Roderick T Bronson; Michael D Taylor; Kyuson Yun
Journal:  Cancer Res       Date:  2014-08-18       Impact factor: 12.701

Review 4.  Epigenetic regulation in medulloblastoma.

Authors:  Jiaqing Yi; Jiang Wu
Journal:  Mol Cell Neurosci       Date:  2017-12-18       Impact factor: 4.314

5.  Pediatric rhabdoid tumors of kidney and brain show many differences in gene expression but share dysregulation of cell cycle and epigenetic effector genes.

Authors:  Diane K Birks; Andrew M Donson; Purvi R Patel; Alexandra Sufit; Elizabeth M Algar; Christopher Dunham; B K Kleinschmidt-DeMasters; Michael H Handler; Rajeev Vibhakar; Nicholas K Foreman
Journal:  Pediatr Blood Cancer       Date:  2013-02-04       Impact factor: 3.167

6.  MicroRNA 218 acts as a tumor suppressor by targeting multiple cancer phenotype-associated genes in medulloblastoma.

Authors:  Sujatha Venkataraman; Diane K Birks; Ilango Balakrishnan; Irina Alimova; Peter S Harris; Purvi R Patel; Michael H Handler; Adrian Dubuc; Michael D Taylor; Nicholas K Foreman; Rajeev Vibhakar
Journal:  J Biol Chem       Date:  2012-12-04       Impact factor: 5.157

Review 7.  Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications.

Authors:  Wei Wang; Jiang-Jiang Qin; Sukesh Voruganti; Subhasree Nag; Jianwei Zhou; Ruiwen Zhang
Journal:  Med Res Rev       Date:  2015-07-30       Impact factor: 12.944

8.  Enhancer of Zeste Homolog 2 Inhibition Attenuates Renal Fibrosis by Maintaining Smad7 and Phosphatase and Tensin Homolog Expression.

Authors:  Xiaoxu Zhou; Xiujuan Zang; Murugavel Ponnusamy; Monica V Masucci; Evelyn Tolbert; Rujun Gong; Ting C Zhao; Na Liu; George Bayliss; Lance D Dworkin; Shougang Zhuang
Journal:  J Am Soc Nephrol       Date:  2015-12-23       Impact factor: 10.121

Review 9.  Medulloblastomics: the end of the beginning.

Authors:  Paul A Northcott; David T W Jones; Marcel Kool; Giles W Robinson; Richard J Gilbertson; Yoon-Jae Cho; Scott L Pomeroy; Andrey Korshunov; Peter Lichter; Michael D Taylor; Stefan M Pfister
Journal:  Nat Rev Cancer       Date:  2012-12       Impact factor: 60.716

10.  [Therapeutic effect of enhancer of Zeste homolog 2 inhibitor GSK343 on periodontitis by regulating macrophage differentiation].

Authors:  Wang Zhongchao; Fan Liyuan; Tan Dan; Zhou Cong; Luo Shijun
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2017-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.